|
Cycle 1 (Predose)a
|
Cycle 2
|
Cycle 3
|
Cycle 4
|
Cycle 5
|
Cycle 6
|
Cycle 7
|
EOT
|
|---|
|
Patients with relapsed or refractory ALL who received single-agent InOb
|
|
x
| | |
x
| | | |
x
|
|
x
|
x
|
x
|
x
|
x
|
x
| |
x
|
|
Patients with relapsed or refractory NHL who received single-agent InOc
|
|
x
|
x
|
x
|
x
|
x
| |
x
|
x
|
|
x
|
x
|
x
|
x
|
x
| |
x
|
x
|
|
x
| |
x
| | | | |
x
|
|
Patients with relapsed or refractory NHL who received InO plus rituximabc
|
| |
x
|
x
|
x
|
x
| |
x
|
x
|
| |
x
|
x
|
x
|
x
| |
x
|
x
|
|
x
| | | | | | | |
|
x
| | |
x
| | | |
x
|
|
x
|
x
|
x
|
x
|
x
|
x
| |
x
|
|
Patients with relapsed or refractory NHL who received InO plus rituximab plus chemotherapyc
|
|
x
| | |
x
| | | |
x
|
- Samples taken predose for respective treatment cycles
- ALL acute lymphoblastic leukemia, ECL electrochemiluminescence, ELISA enzyme-linked immunosorbent assay, EOT end of treatment, InO inotuzumab ozogamicin, NHL non-Hodgkin lymphoma
- aBefore first InO treatment. May have been omitted if sample taken at screening
- bECL assay
- cELISA
